Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of JNJ-54175446 Solid Dosage vs Suspension
NCT02930694Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-54175446 in major depressive disorder (MDD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Plasma Concentration and 5 more. Started Oct 2016; status: completed.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02930694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930694.